Diabetes (Type 2 ), taking METFORMIN

  • STATUS
    Not Recruiting
  • sponsor
    Merck
Updated on 23 November 2020

Summary

Diabetes (Type 2 ), taking METFORMIN

Description

Merck is conducting a clinical research study for adults who are at least 25 years of age and have been diagnosed with type 2 diabetes. The purpose of this study is to compare the safety and effectiveness of the oral medications sitagliptin versus dapagliflozin for the treatment of type 2 diabetes as an add-on to metformin. The use of these medications combined with metformin is investigational.

Approximately 550 volunteers around the world will participate in this clinical research study.

The study medication will be provided to study participants at no charge. Nutrition and exercise counseling will also be provided.

The purpose of the study is to assess the effect of the addition of sitagliptin to metformin compared with the addition of dapagliflozin to metformin on hemoglobin A1c (A1C) over 24 weeks of treatment

7 VISITS TOTAL

ClinicalTrials.gov identifier: NCT02532855

ClinicalTrials.gov identifier: NCT02532855

Details
Condition NIDDM
Clinical Study IdentifierTX144229
SponsorMerck
Last Modified on23 November 2020

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note